The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...
Read More
A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.
Read More 
The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.
Read More 
Dr. Jeffrey Glenn is a Professor of Medicine, Microbiology & Immunology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He is the founder of Eiger Biopharmaceuticals who is developing Lambda for hepatitis delta and COVID.
Dr. Glenn is an author on over 100 scientific articles and book chapters, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. He is the principal investigator on multiple NIH grants, and a member of FDA Antiviral Drugs.
He is an international authority on developing novel antiviral therapeutics.
